Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

P-235 Elevated protein tyrosine phosphatase kappa expression is associated with disease progression and poor prognosis of pancreatic cancer

Fang, Z., Jiang, W. ORCID: and Ye, L. ORCID: 2022. P-235 Elevated protein tyrosine phosphatase kappa expression is associated with disease progression and poor prognosis of pancreatic cancer. Annals of Oncology 33 (S4) , S332-S332. 10.1016/j.annonc.2022.04.325

Full text not available from this repository.
License URL:
License Start date: 2 July 2023


Background Protein tyrosine phosphatase kappa (PTPRK) is a phosphatase which is recognised as a tumour suppressor. PTPRK can promote the internalization of ZNRF3 by dephosphorylating CD133. It is a negative regulator of the invasion and adhesion of breast cancer cells, what is more, it is also enhance the activation of STAT3 in lung cancer. Pancreatic exocrine cancer is an extremely aggressive tumour with a mortality being nearly equal to its incidence. The aim of present study is to assess the involvement of PTPRK in the disease progression of pancreatic cancer. Methods PTPRK transcripts were determined in pancreatic cancers (n=201) and adjacent non-tumour pancreatic tissues (n=201) using real time PCR. The pancreatic tissue samples were collected immediately after surgery at Peking University Cancer Hospital. All procedures used are approved by the Peking University Cancer Hospital Research Ethics Committee. The implication of PTPRK in disease progression and prognosis was analysed which was also further supported by analyses of RNAseq data of pancreatic cancer (The Cancer Genome Atlas, TCGA_PAAD) and a gene array data (GSE15471 and GSE71729). Further bioinformatic analysis has been done to determine which pathway is regulated by PTPRK. Results Both the public dataset GSE15471 and the Beijing clinical cohort shows increased PTPRK expression in the tumours compared with adjacent normal tissue. PTPRK expression in tumours of the earliest stage (T1) is lower than more invasive tumours (T2, T3 and T4). However, PTPRK tends to be lower in primary tumours that presented lymph node metastases. There is no significant change of PTPRK expression in the primary tumours that developed distant metastases. Moreover, PTPRK is down regulated in distant metastatic tumours from pancreatic cancer (GSE71729). Compared with lesions in the tail of pancreas, the PTPRK has also been found has a higher expression level in pancreatic head and body. Pancreatic cancer patients with a higher PTPRK level had poor overall and relapse free survival compared with patients with tumours of low PTPRK expression. In the TCGA PAAD cohort, PTPRK is positively correlated with some RTKs family gene, including EGFR, KDR, FGF and PDGF. However, neither protein level of EGFR nor phosphorylation of EGFR (Y1068 and Y1173) presented obvious difference according to PTPRK transcripts in the corresponding tumours. Conclusions The PTPRK is involved in pancreatic cancer progression, it is associated with a poor prognosis. Exact role played by PTPRK in pancreatic cancer and its predictive and therapeutic potential are yet to be fully investigated using both in vitro and in vivo models.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Additional Information: License information from Publisher: LICENSE 1: URL:, Start Date: 2023-07-02
Publisher: Elsevier
ISSN: 0923-7534
Last Modified: 30 Nov 2022 08:15

Actions (repository staff only)

Edit Item Edit Item